Boston Trust Walden Corp Trims Position in Medpace Holdings, Inc. $MEDP

Boston Trust Walden Corp lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 140,610 shares of the company’s stock after selling 7,391 shares during the quarter. Boston Trust Walden Corp’s holdings in Medpace were worth $67,520,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace in the 4th quarter worth about $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace during the 4th quarter valued at about $30,000. Quarry LP acquired a new position in shares of Medpace during the 3rd quarter valued at about $35,000. Bayban purchased a new position in shares of Medpace during the 4th quarter worth about $44,000. Finally, Core Wealth Advisors LLC purchased a new position in shares of Medpace during the 4th quarter worth about $47,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

NASDAQ MEDP opened at $557.60 on Friday. The firm has a market capitalization of $15.93 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $306.70 and a one year high of $628.92. The company’s 50 day moving average price is $452.89 and its 200 day moving average price is $496.20.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the firm earned $3.67 earnings per share. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on MEDP shares. BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Barclays cut their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Robert W. Baird decreased their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.